Table 4.
Univariate and multivariate Cox regression analysis for disease-free survival (DFS) and overall survival (OS) at 24 months
| DFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate Cox analysis | Multivariate Cox analysis | Univariate Cox analysis | Multivariate Cox analysis | |||||
|
| ||||||||
| Variable | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value |
|
| ||||||||
| Age [< 65y vs. ≥65y] | 0.6 [0.2–1.9] | 0.315 | 0.04 [0–25.4] | 0.323 | ||||
|
| ||||||||
| ECOG PS [0 vs. >1] | 1.6 [0.7–3.6] | 0.248 | 1.4 [0.4–5.0] | 0.640 | ||||
|
| ||||||||
| Premenopausal status | 0.8 [0.4–1.7] | 0.592 | 0.7 [0.2–2.3] | 0.612 | ||||
|
| ||||||||
| BRCA mutation | 3.0 [1.0–8.6] | 0.045 | 0.6 [0.1–2.7] | 0.487 | 1.6 [0.2–12.7] | 0.639 | ||
|
| ||||||||
| MBR grade [< 3 vs. 3] | 1.5 [0.8–2.8] | 0.224 | 1.3 [0.5–3.3] | 0.567 | ||||
|
| ||||||||
| Ki67 [< 70% vs. ≥ 70%] | 1.6 [0.7–3.5] | 0.245 | 2.0 [0.5–7.5] | 0.290 | ||||
|
| ||||||||
| Clinical T status, cT [1–2 vs. 3–4] | 2.3 [1.0–5.4] | 0.056 | 1.9 [0.5–7.0] | 0.336 | ||||
|
| ||||||||
| Clinical nodal status cN [0 vs. ≥ 1] | 1.2 [0.6–2.7] | 0.579 | 0.7 [0.2–2.3] | 0.582 | ||||
|
| ||||||||
| Clinical stage [II vs. III] | 0.2 [0.1–1] | 0.053 | 0.4 [0.05–2.7] | 0.317 | ||||
|
| ||||||||
| Pretreatment N/L ratio [< 1.8 vs. ≥ 1.8] | 1.5 [0.7–3.3] | 0.288 | 2.4 [0.6–8.7] | 0.197 | ||||
|
| ||||||||
| Pretreatment P/L ratio [< 0.1 × 103vs. ≥0.1 × 103] | 1.2 [0.6–2.5] | 0.651 | 0.9 [0.3–2.8] | 0.825 | ||||
|
| ||||||||
| CEA ratio | 1 [0.4–2.3] | 0.942 | 0.4 [0.1–3.1] | 0.380 | ||||
|
| ||||||||
| CA 15.3 ratio | 2.3 [0.8–6.6] | 0.129 | 1.0 [0.1–7.8] | 0.993 | ||||
|
| ||||||||
| Neoadjuvant radiotherapy | 0.2 [0.1–0.5] | < 0.001 | 2.8 [1.2–6.4] | 0.017 | 0.1 [0.04–0.4] | 0.001 | 7.5 [2.4–23.2] | 0.001 |
|
| ||||||||
| Adjuvant radiotherapy | 1.3 [0.6–2.7] | 0.456 | 1.1 [0.4–3.5] | 0.860 | ||||
|
| ||||||||
| Adjuvant chemotherapy | 0.6 [0.2–2.1] | 0.460 | 0.3 [0.1–1.6] | 0.167 | ||||
|
| ||||||||
| pCR | 5.1 [1.9–13.3] | 0.001 | 0.3 [0.1–1.7] | 0.011 | 10.1 [1.3–78.5] | 0.027 | 0.2 [0.02–1.4] | 0.102 |
|
| ||||||||
| Lymph nodes removed [< 10 vs. ≥ 10] | 0.8 [0.4–1.9] | 0.661 | 0.9 [0.3–3.4] | 0.915 | ||||
|
| ||||||||
| Pathologic node status pN [N0 vs . N+] | 0.3 [0.1–0.6] | < 0.001 | 2 [0.9–4.6] | 0.098 | 0.4 [0.1–1.3] | 0.146 | ||
|
| ||||||||
| Pathologic T status pT [< 3 vs . ≥3] | 0.3 [0.1–0.8] | 0.015 | 1.8 [0.6–5.3] | 0.288 | 0.3 [0.1–1.2] | 0.085 | ||
|
| ||||||||
| Pathologic celularity [0–5% vs . >5%] | 2.9 [1.2–7.1] | 0.021 | 1.5 [0.6–4.3] | 0.408 | 3.5 [0.8–15.9] | 0.108 | ||
|
| ||||||||
| Pathologic LVI | 2.2 [1.0–4.9] | 0.065 | 2.8 [0.8–9.1] | 0.102 | ||||
|
| ||||||||
| Pathologic deep margin involvement | 1.6 [0.4–6.6] | 0.545 | 1.9 [0.2–14.9] | 0.532 | ||||
LVI — lymphovascular invasion; ECOG PS — Eastern Cooperative Oncology Group performance status; MBR — Modified Bloom Richardson pathologic grade; pCR — pathologic complete response